ArticleNucleic acids research2026
Cancer epitope prediction tools and analysis pipelines in CEDAR.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Cancer Epitope Database and Analysis Resource (CEDAR): current capabilities and future directions.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Accurate identification of immunogenic cancer epitopes remains a central challenge in immuno-oncology. The Cancer Epitope Database and Analysis Resource (CEDAR, https://cedar.iedb.org/) was developed to provide comprehensive curation of experimentally validated epitopes and to foster the development of computational tools tailored to the cancer context. Recently, we released a suite of cancer-specific tools and analysis pipelines as part of the https://nextgen-tools.iedb.org/ platform, enabling users to generate, evaluate, and prioritize candidate T cell epitopes in a modular framework. Here, we present the design and functionality of these tools, describe their core methodologies, provide guidance for their use, and illustrate how they can be integrated into end-to-end pipelines. We highlight applications in cancer immunology and personalized immunotherapy by presenting practical use cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.